Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ) has shared an update. Infant Bacterial Therapeutics AB has partnered with ...
EU Commissioner for Enlargement Marta Kos looks at a production hall damaged after a recent Russian missile attack at DTEK's ...
In a significant leap forward, Birla Opus Paints, part of the Grasim Industries family, has transformed its operations ...
Monster Beverage gains global market share with Ultra line, strong margins, emerging market penetration, and supply chain ...
Oil majors operating in Brazil have closed ranks to oppose a proposed merger between energy contractors Subsea7 and Saipem, ...
IBP-9414 will be the first live biotherapeutic product globally, according to officials at Infant Bacterial Therapeutics in Stockholm.
Abstract: Polyethylene, PE for short, is a thermoplastic resin made by polymerization of ethylene. With the development of the petrochemical industry, polyethylene production has been developed ...
Following today's meeting with the FDA concerning IBT's live biotherapeutic product, IBT has decided to pursue an accelerated approval pathway for IBP-9414. The FDA's Accelerated Approval Program allo ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...